The Patent Finder

Contera Pharma A/S

6 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 17, 2027
    The maintenance fee for Combinations of serotonin receptor agonists for treatment of movement disorders (US 9,186,359) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
  • 1 fee due Aug 18, 2027
    The maintenance fee for Orally available pharmaceutical formulation suitable for improved management of movement disorders (US 10,561,618) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Combinations of serotonin receptor agonists for treatment of movement disorders (US 10,632,116) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Pulsatile Drug Delivery System for Treating Morning Akinesia (US 11,975,104) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,186,359Combinations of serotonin receptor agonists for treatment of movement disorders
In force
 · USPTO record
In forceUSPTO record
US 10,632,116Combinations of serotonin receptor agonists for treatment of movement disorders
In force
 · USPTO record
In forceUSPTO record
US 10,561,618Orally available pharmaceutical formulation suitable for improved management of movement disorders
In force
 · USPTO record
In forceUSPTO record
US 11,478,476Use of buspirone metabolites
In force
 · USPTO record
In forceUSPTO record
US 11,975,104Pulsatile Drug Delivery System for Treating Morning Akinesia
In force
 · High confidence
In forceHigh confidence
US 12,773,389Pulsatile Drug Delivery System for Treating Morning Akinesia
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 2 no status recorded

Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
17/930,169Pulsatile Drug Delivery System for Treating Morning AkinesiaSep 7, 2022Abandoned
17/415,236Dec 20, 2019No status recorded
14/126,630Jul 5, 2012No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited